Free Alerts   Login
Health Care › Ophthalmic Goods

RXST Stock Price Correlated With RxSight Financials

RXST Stock Price vs. Quarterly
RXST
Income Statement
Cash Flow
Balance Sheet

RXST Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

RXST Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

RXST Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Tammenoms Bakker Juliet   Director
8,000 sh at $51
$406,673
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Ra Capital Management, L.P.
3,404,285 sh
351,489 sh
12%
$137,261
$52,119
Artisan Partners Limited Partnership
2,395,672 sh
-42,093 sh
-2%
$96,593
$28,604
Blackrock.
2,076,470 sh
223,381 sh
12%
$83,725
$32,043
Lord, Abbett & Co.
1,977,000 sh
348,680 sh
21%
$80
$34
Vanguard Group
1,484,010 sh
50,057 sh
3%
$59,835
$19,842
FMR
1,186,477 sh
1,185,612 sh
137065%
$47,839
$47,815
Morgan Stanley
1,073,062 sh
-138,342 sh
-11%
$43,265
$9,480
T. Rowe Price Investment Management.
958,105 sh
958,105 sh
NEW
$39
$39
Deutsche Bank Ag\
706,394 sh
692,630 sh
5032%
$28,482
$28,099
State Street
703,967 sh
6 sh
0%
$28,384
$8,751
Nuveen Asset Management
695,705 sh
264,228 sh
61%
$28,051
$16,017
Next Century Growth Investors
657,021 sh
-90,806 sh
-12%
$26,491
$5,634
JPMorgan Chase
596,540 sh
44,975 sh
8%
$24,053
$8,670
Geode Capital Management
558,507 sh
40,368 sh
8%
$22,521
$8,068
Bank Of America /De/
538,550 sh
-94,644 sh
-15%
$21,714
$4,054
Driehaus Capital Management
529,220 sh
-64,738 sh
-11%
$21,338
$4,773
Parkman Healthcare Partners
513,032 sh
14,401 sh
3%
$20,685
$6,324
Atika Capital Management
444,000 sh
-65,352 sh
-13%
$17,903
$3,697
No Street Gp Lp
425,000 sh
425,000 sh
NEW
$17,136
$17,136
Northernrp
329,520 sh
90,326 sh
38%
$13,287
$6,616
COMPANY PROFILE
Note 1 - Organization and Basis of Presentation Description of Business RxSight®, Inc. (the “Company”) is a Delaware corporation headquartered in Aliso Viejo, California with one wholly owned subsidiary located in Amsterdam, Netherlands. The wholly owned subsidiary has a registered branch in the United Kingdom and a wholly owned subsidiary located in Germany. The Company is engaged in the research and development, manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses. The Company’s products, which include the light adjustable lens (“LAL”®) and a specially designed machine for delivering light to the eye, the Light Delivery Device (“LDD™”), are approved by the United States (“U.S.”) Food and Drug Administration (“FDA”) for sale in the U.S. and have regulatory approval in the U.S and Europe. The Company began marketing its products in the U.S. during the second quarter of 2019 and in Europe during the third quarter of 2019. The LAL is a premium intraocular lens (“IOL”) which is partially reimbursable under Medicare. The Company competes with other IOLs in the premium market in the U.S. and Europe. The accompanying unaudited condensed consolidated financial statements include the accounts of RxSight, Inc. and its wholly owned subsidiaries, RxSight, B.V., and RxSight GmbH. All significant inter-company balances and transactions have been eliminated in consolidation. Basis of Presentation and Principles of Consolidation The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The unaudited interim financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The December 31, 2021 balance sheet data was derived from audited financial statements; however, the accompanying notes to the condensed consolidated financial statements do not include all of the annual disclosures required under GAAP and should be read in conjunction with the Company’s 2021 Annual Report on Form 10-K filed with the SEC on March 8, 2022. The operating results presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods.

Initial Public Offering ( “ IPO ” ) and Reverse Stock Split On July 22, 2021, the Company’s Board of Directors (“Board”) approved an amendment to the Company’s certificate of incorporation to effect a reverse split of shares of the Company’s common stock, excluding Series G and Series W common stock, and convertible preferred stock on a 1-for-10.33 basis (“Reverse Stock Split”). The par values of the common stock and convertible preferred stock were not adjusted as a result of the Reverse Stock Split. The Reverse Stock Split was effected on July 23, 2021. Accordingly, all common stock, excluding Series G and Series W common stock, options to purchase common stock, convertible preferred stock, share data, per share data and related information contained in the accompanying condensed consolidated financial statements and notes have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The Reverse Stock Split resulted in an adjustment to the convertible preferred stock conversion price

Free historical financial statements for RxSight Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 11 quarters since 2021. Compare with RXST stock chart to see long term trends.

Data imported from RxSight Inc. SEC filings. Check original filings before making any investment decision.